



Press release 2013-12-23

First Sales of Catalyst HD™

The Catalyst HD™ system, especially designed for use in proton therapy and for advanced stereotactic treatments, has been released. The installations of the first two systems in Europe are ongoing.

Catalyst HD™ is based on the patented C-RAD technology. With a unique arrangement of multiple 3D cameras and newly developed software, the system is convincing with superior performance for all treatments where couch rotations are applied.

All interfaces for respiratory gating and for treatment couch control, will be compatible and used with the Catalyst HD™. Existing software modules for Patient Setup and Positioning, Motion Monitoring during treatment and Respiratory Gating are adopted to the new system. Stereotactic radiosurgery is a form of radiation therapy where the focused x-ray beam is delivered with very high accuracy into a small volume within the body. Therewith tumor tissue can be treated efficiently with minimizing the dose delivered to healthy tissue around the tumor. This treatment technique is especially used for head and neck treatments.

Tim Thurn, CEO of C-RAD AB:

“With the presentation of Catalyst HD C-RAD answers the high demands of advanced clinicians and underlines its role as market leader in the field of surface tracking. The interest for the new Catalyst HD has been overwhelming. A number of quotations are pending both in Europe and in the US.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™ started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com